May 29, 12:24 PM

Biohaven's Protein-Degrader Drug Disappoints Investors, BHVN Stock Plummets 26.2% - SEC Filings and Presentation Deck Data Awaited

Biohaven's protein-degrader drug, not BHV-1300, falls short of investor expectations in early tests, leading to a 26.2% pre-market drop in BHVN stock. The company will provide more data from SEC filings and presentation deck to address concerns.

#Biohaven #SEC

Written with ChatGPT (GPT-3).

Sources

Adam Feuerstein ✡️@adamfeuerstein
2 years ago
Updated with comments from CEO Vlad Coric: $BHVN Biohaven protein-degrader drug falls short of investor expectations in early-study test https://t.co/D6rPMy3lS3
Open Outcrier@OpenOutcrier
2 years ago
$BHVN (-26.2% pre) Biohaven Pharma (BHVN) Falls Following Updates from Annual Investor R&D Day - SI https://t.co/cpvn6sKPmU
Matthew Herper@matthewherper
2 years ago
Biohaven protein-degrader drug falls short of investor expectations in early test https://t.co/XT2Zl7qgpY

Biohaven's Protein-Degrader Drug Disappoints Investors, BHVN Stock Plummets 26.2% - SEC Filings and Presentation Deck Data Awaited

Sources

Additional media

Similar Stories